格鲁吉亚

我们是谁

  • 4 月 5, 2022
    TAS102 与 NAL-IRI 联合治疗晚期消化道癌症
  • 4 月 5, 2022
    TAPUR：测试食品药品管理局（FDA）批准的针对晚期癌症患者肿瘤基因特定异常的药物的使用情况
  • 4 月 5, 2022
    A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
  • 4 月 5, 2022
    Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
  • 4 月 5, 2022
    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
  • 4 月 5, 2022
    CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)